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Abstract
Background: To extend the potency of vaccines against infectious diseases, vaccines should be able to exploit
multiple arms of the immune system. One component of the immune system that is under-used in vaccine design
is the subset of B cells known to be capable of responding to repetitive antigenic epitopes and differentiate into
plasma cells even in the absence of T cell help (T-independent, TI).
Results: To target vaccine responses from T-independent B cells, we reengineered a bacterial Flagellin (FliC) by
replacing its exposed D3 domain with a viral envelope protein from Dengue virus (DENV2). The resulting hybrid
FliC protein (hFliC) was able to form stable filaments decorated with conformationally intact DENV2 envelope
domains. These filaments were not only capable of inducing a T cell-dependent (TD) humoral antibody response,
but also significant IgM and IgG3 antibody response in a helper T cell repertoire-restricted transgenic mouse model.
Conclusions: Our results provide proof-of-principle demonstration that a reengineered hybrid FliC could be used as
a platform for polymeric subunit vaccines, enhancing T cell-dependent and possibly inducing T-independent antibody
responses from B-1 B cells as well.
Background
Adaptive immune antibody responses rely primarily on
the interaction between T helper cell populations promot-
ing B cell activation, isotype switching, and development of
plasma cells producing immunoglobulin, with subsequent
pathogen opsonization/viral neutralization [1–3]. However,
in T cell-deficiency settings such as AIDS, this TD mode of
antibody production is ineffective at conferring protection
to the host. Fortunately, “innate-like” B cells, which include
splenic marginal zone B cells (15 % of total B cells) and
peritoneal B1 B cells (B1a and B1b, 3 % of total of B cells),
can become activated after recognition of repetitive or poly-
meric antigenic epitopes causing B cell receptor (BCR)
clustering, independently of T helper (Th) subset (TI: [4,
5]). Efficient BCR clustering is crucial for the generation of
a TI antibody response and in fact it has been determined
that 10–20 BCRs must be crosslinked in order to mount a
TI response [6, 7]. On resting B cells, BCRs are spaced ap-
proximately 35 nm apart, requiring TI antigens to be at
least 500 nm in length [7]. Despite the chemical diversity of
TI antigens, most TI antigens repetitive epitopes are spaced
5–10 nm [6, 8]. Once a TI B cell has become activated,
its antibody response is largely characterized by the
production of IgM and certain IgG isotypes (IgG3 and
possibly IgG1: [9]). B1 B cells have also been found to
undergo class switch recombination from IgM to IgA.
Although the anatomic site of this isotype switch remains
elusive, this suggests that a significant proportion of IgA
may be generated in a TI manner [10].
While many bacterial capsular polymeric components
have been studied for their ability to stimulate a TI antibody
response, it remained to be tested whether bacterial flagellin
(FliC), a major antigen present on many commensal and
pathogenic microbes, can be exploited as a scaffold for TI
vaccines [11, 12]. Indeed, one study suggested that poly-
meric flagellin, like its monomeric form, relies on T cell
help to stimulate a humoral immune response. However,
this study did not include IgM and IgG3 (two major anti-
body isotypes indicative of TI response) in their analysis
[13]. FliC from Salmonella serovar enterica typhimurium
(S. Typhimurium) is the major protein making up the fla-
gellum (11-fold symmetry) and can grow to 15 μm in
length [14]. In vitro studies revealed that FliC is able to
form filaments hundreds of nanometers in length [15]. This
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is a critical feature for the success of TI vaccines, as it
has been suggested that a TI antigen needs to be at least
500 nm in length to produce a significant TI response.
FliC is a four-domain (D0, D1, D2, D3) protein that
structurally resembles the Greek letter Γ (Fig. 1), and has
been well characterized for its adjuvant activity due to
its Toll-like receptor 5 (TLR5) and Nod-like receptor
CARD domain-containing protein 4 (NLRC4) binding
sites located in its D1 domain, a domain also responsible
for polymerization [14, 16–18]. In polymerized FliC
filaments, the D3 domain of FliC is completely solvent
exposed, while other domains remain mostly buried
within the inner core. Moreover, based on the crystal-
lographic structure of the Filament the D3 domains
are spaced ~5 nm apart. Muskotal et al. [19] found that as
a monomer the D3 domain is the most stable portion
of FliC, where D0 and D1 completely lose their α-helical
secondary structure, corroborating previous structural
studies. Moreover, by eliminating D3, this study found
that D3 was dispensable for the overall stability of the
flagellum filament, marking D3 as a possible insertion
site for novel antigenic determinants.
The polymeric nature of FliC filaments intrinsically
provides the key feature needed for stimulating a potent
TI response, so we wanted to test its ability as a vaccine
scaffold for TI antigens. Our approach was to test the
FliC D3 site for insertion of a fully independent con-
formational domain, and polymerizing the engineered
protein as a vaccine target. We engineered native FliC
by replacing its entire D3 domain with the full length se-
quence of the Envelope glycoprotein (E) from Dengue
virus serotype 2 (E), bridged by flexible linker sequences.
This allowed for the antigen portion of the hybrid FliC
(hFliC) protein to be fully exposed in polymerized
Fig. 1 Design and analysis of hybrid flagellin protein. a Schematic of the construction and design of hybrid flagellin (hFliC). The D3 domain from
the native FliC protein was deleted (residues 185 to 285). DENV2 E plus GS linkers flanking the termini were inserted to replace the D3 domain of
FliC. The final gene product was cloned into the pENTR plasmid for baculovirus expression of the hybrid protein. b Protein expressed by baculovirus
expression system was checked for purity and anticipated molecular weight (~85 kDa) using both Coomassie stain (left panel, which labels all proteins)
and Western blot (right panel). In the Western blot, protein was probed with an antibody against the His-tag under denaturing conditions. Major bands
from both blots indicate appropriate band size, however some degradation products were present in Coomassie gel; by densitometry the predicted
hFliC band comprised approximately 15 % of total protein. The double band in the Western blot suggests a proteolytic cleavage very near
the N-terminus. c Circular dichroism (CD) was used to assess secondary structural feature of the hFliC protein. CD spectra of FliC (blue curve)
exhibit a characteristic α-helical region, while DENV2 spectra (green curve) exhibit a large β-sheet and coil regions. hFliC CD spectra (red
curve) was essentially a hybrid of the two proteins
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filaments, enabling engagement of the antigen with
the B cell antigen receptors for BCR crosslinking and
subsequent TI stimulation. Our studies showed that
the hFliC filaments were able to stimulate a potent anti-
body response; more importantly, the filament induced a
significant response in a helper T cell-restricted mouse
model. Thus, the study presented herein describes the
use of FliC as a novel scaffold for the design of potential
TD/TI vaccines.
Results
Design and characterization of hFliC protein
To take advantage of the solvent exposed location of the
D3 domain of FliC, we replaced this domain with a vaccine
antigen domain, so that the surface of the polymerized
hybrid protein filament would present polymeric vaccine
antigen instead of flagellin epitopes. Thus, the flagellin D3
domain from residues 185 to 285 were removed and re-
placed with the extracellular domain of the DENV2 enve-
lope protein (Dengue 2 E: Fig. 1a). DENV2 E is one of
three structural proteins produced by the Dengue 2 virus
(there are 4 identified Dengue serotypes, sharing ~70 %
genome homology) and forms an icosahedral scaffold at
the virion surface. DENV2 E mediates the fusion of virus
to host cells and as such has been extensively studied for
its antigenicity as a DENV2 vaccine [20]. In order to main-
tain the conformational independence of this domain, we
added Gly-Ser flexible linkers to join FliC to the N- and
C- terminus of DENV2 E. The resulting hybrid protein is
therefore comprised of a central independent DENV 2 E
protein domain, flanked by the two independent N-and C-
terminal helical domains of FliC; folding of the E protein
domain will help stabilize the helical domains of FliC,
although further stabilization occurs in the polymerized
filament when interactions between helical domains of
the monomers interact. Finally, a C-terminal His6-tag
was added for production and purification purposes.
The hybrid FliC protein (hFliC) was produced using a
baculovirus expression system, purified (Fig. 1b), and
subsequently assayed for appropriate structure and func-
tion. After His-tag enrichment, the hFliC band is clearly
evident although comprising only about 14 % of total pro-
tein; Western blot indicates a possible proteolytic cleavage
near the N-terminus.
Circular dichroism (CD) was used to assess the secondary
structure of purified hFliC protein (Fig. 1c), and compared
to that of free FliC and DENV2. Quantification of percent
secondary structure from the CD spectra revealed that FliC
(protein size and purity confirmed: Additional file 1: Figure
S1A) was largely α-helical, Meanwhile, DENV2 (protein
size and purity confirmed: Additional file 1: Figure S1b)
had a larger β-sheet region, consistent with previous pub-
lished spectra, and was in good agreement with computa-
tionally determined secondary structure percentages based
on crystallographic structures (Table 1: [21]). The hybrid
hFliC exhibited a spectrum of mixed α-helical and β-sheet
character (Fig. 1c). Taken together these data suggest that
whole protein antigens can be inserted into FliC backbone
without jeopardizing the native secondary structure of
either protein.
Characterization of hFliC filaments
A hypothetical molecular model of the hFliC filament
predicts an independent domain of DENV E at the surface
of an intact 11-protofilament polymer (Fig. 2a). Accord-
ingly, we determined that the hFliC protein was able to
form filaments in high molar ammonium sulfate or so-
dium citrate (Fig. 2a and data not shown), similar to
the reported molar conditions for in vitro WT FliC
polymerization [15]. To evaluate these filaments, we
used negative stain transmission electron microscopy
(TEM). Morphometric analysis of the filaments revealed
an increased diameter of 35 nm compared to WT FliC
filaments (diameter of ~20 nm [14]), consistent with
the hypothetical molecular model of the hFliC filament
(Fig. 2a). However, we do not have sufficient resolution
to confirm that the hFliC forms the prototypical 11-
protofilament core structure as suggested by the hypo-
thetical molecular model.
The inner core of the hFliC filaments exhibited a high
degree of contrast, comparable to Tobacco Mosaic Virus
(TMV) filaments (known to have high contrast) (Additional
file 1: Figure S2a,b). However, the outer regions of the fila-
ments displayed a low degree of contrast relative to the rest
of the filament suggesting that individual DENV2 antigen
domains were able to rotate freely at the surface of the fila-
ment (further confirmed via cryoelectron microscopy, data
not shown). This flexibility might be beneficial to the avidity
of the DENV2 antigenic domain of the polymeric hFliC
vaccine.
To confirm that the DENV2 E domain retained its an-
tigenicity, we used a DENV2 specific recombinant IgA
monoclonal antibody (Additional file 1: Figure S3a,b);
this antibody was produced from sequences derived from
Table 1 Quantification of secondary structure from CD spectra
% of Secondary Structure α-helix β-Sheet Random coil
FliC
Computationally determineda 43.00 21.00 35.00
Experimentally determinedb 71.10 7.20 21.70
DENV2 E protein
Computationally determineda 7.00 48.00 55.00
Experimentally determinedb 2.03 39.21 58.00
hFliC
Experimentally determinedb 56.00 18.40 25.60
aCalculated using Stride
bCalculated using k2d3
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the DENV2-specific 4G2 hybridoma because we discov-
ered that the original hybridoma produced mixed antibody
complexes, not all being specific for DENV2 E protein.
We tested the recombinant IgA binding to control recom-
binant DENV2 E domain, as well as in the hybrid hFliC
protein and polymerized hFliC filament. In an ELISA
assay, the DENV2 E hFliC was able to bind the 4G2 IgA
(Fig. 2b, negative control FliC alone).
More importantly, we also confirmed that DENV2 E
epitopes were available on the surface of the polymerized
filament. This was confirmed by immunogold labeling of
the hFliC filament using DENV2 specific IgG produced
by the 4G2 hybridoma (Fig. 2c). The 4G2 antibody is
known to bind/recognize an epitope region in the ex-
tremity of domain DII (important for membrane fusion)
of the DENV2 E protein; based on our hFliC molecular
model, this is the domain most solvent exposed in fila-
ment formation (Fig. 1a: [22, 23]). Together, these data
demonstrate 1) that the hFliC protein is able to form fil-
aments in a similar manner to WT FliC, 2) the DENV2
Fig. 2 Characterization of hybrid flagellin filaments. a The top panel represents molecular structure of the parent FliC filament13 (left panel: XY
view and middle panel: Z view). Negative stain TE micrograph of WT FliC filament generated by recombinantly produced FliC (right panel); FliC
filament diameter was calculated to be 20 nm. The bottom panel represents a hypothetical molecular model of hFliC, where DENV2 + GS linkers
were modeled into native FliC filament to replace D3 domain. The diameter of hFliC was computationally determined to be 35 nm. Negative
stain TE micrographs confirmed resulting hFliC filaments had increased diameter compared to FliC filament. b Binding ELISA was performed
using DENV2 specific monoclonal IgA antibody. hFliC showed binding to monoclonal IgA, compared to FliC alone, which showed no binding.
Experiments were performed in triplicate (n = 3), and error bars represent mean +/- SEM, Student’s t-test was used to determine statistics, and a
p < 0.05 were considered statistically significant. c Immunogold particle labeling against DENV2 E specific IgG (primary antibody, isolated from
4G2 culture supernatant), was used to determine the placement of the DENV2 E portion relative to the rest of the filament. Negative stain transmission
electron micrograph of immunogold labeling of WT FliC filaments (left panel), confirming that no immunogold particles bound to WT filaments. Right
panel is a negative stain transmission electron micrograph of immunogold labeling of hFliC filaments, which indicated that the immunogold particles
primarily associate with the outside of the hFliC filament
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E subunit inserted into the middle of FliC retains its
conformational independence and 3) its antigenicity is
retained and recognized by anti-DENV2 E-specific
antibody.
In vivo activity of hFliC in TD model
Since we demonstrated that hFliC exhibited proper con-
formation and antigenicity in its polymerized form, we
were ready to test its ability to stimulate an immune re-
sponse in vivo. Using an immunization protocol similar
to that used by Lo et al. [24] but in this case without the
addition of any additional adjuvant (such as cholera
toxin), we tested the immunogenicity of monomeric and
polymeric hFliC in wild type mice (C57BL/6 J; Fig. 3b).
We first administered a priming dose of hFliC filaments
(Fig. 3a) or hFliC monomers, given either intraperitoneally
(IP) or intranasally (IN), followed by three IN booster
doses at one-week intervals for 3 additional weeks.
We found that hFliC filaments induced a stronger
antibody response than their monomeric counterparts in
C57BL/6 J WT mice (Fig. 3c-e and Additional file 1:
Figure S4). IP administration of polymeric hFliC during
the priming injection resulted in the highest serum IgG
(total) and IgM responses (Fig. 3d,e and Additional file
1: Figure S4A,C). Mice given IN priming and booster
injections of polymeric hFliC throughout the immunization
protocol showed the strongest serum IgA response (Fig. 3c
and Additional file 1: Figure S4B). Since different delivery
routes gave different Ig responses in different tissues, we
also tested whether these immunization protocols resulted
in the production of different IgG subclasses (Fig. 3f). Thus,
polymeric hFliC with either IP or IN priming induced
strong serum IgG1 response, while the IP priming dose in-
duced the best IgG2a and IgG2b response. In sum, the IN
priming protocol induced both the best IgA and weakest
IgG2a/b response, consistent with a Th2-type response. By
contrast, the IP priming protocol induced the strongest
IgG2 and IgM responses, though this would not be as easily
categorized as a strict Th1-type response.
hFliC filaments can crosslink BCRs
TI responses rely on the ability of antigens to crosslink
BCRs above a threshold number; this clustering promotes
the T helper cell-independent differentiation of B cells into
plasma cells (Fig. 4a). To determine whether the repetitive
DENV2 E determinants displayed on hFliC filaments were
capable of BCR crosslinking, we tested them on cells ex-
pressing receptors specific for the DENV2 E protein. The
4G2 B cell hybridoma expresses surface Ig receptors spe-
cific for DENV2 E protein, so these cells were incubated
with hFliC filaments. Confocal micrographs of cytospin
slides of unstimulated cells exhibited a randomized distri-
bution of Ig receptors, while cells incubated with hFliC
filaments exhibited a more organized distribution of the
BCRs around the circumference of the cell (Fig. 4b, show-
ing staining of surface Ig). This was further confirmed by
staining with an anti-HisTag antibody (Fig. 4b), suggesting
that the hFliC filament was in direct contact with the BCR
receptors and these receptors had in fact been clustered
by the hFliC filaments.
In vivo activity of hFliC polymers in TCR restricted model
To test the potential for the polymeric vaccine to induce
TI responses, we performed in vivo immunization in a T
cell repertoire-restricted model (Fig. 5a). Here we used a
T cell receptor transgenic mouse model (6.5-TCR, recog-
nizing an influenza hemagglutinin peptide presented on
MHCII I-Ed: [25, 26]), in which nearly all CD4 T cells
express the mono-specific hemagglutinin-specific anti-
gen receptor. Allelic exclusion during thymic selection
would prevent the development of T cells expressing any
additional antigen receptors. This particular transgenic
mouse model was chosen because the degree of allelic
exclusion is more potent in this model compared to most
other models, obviating the need for including additional
targeted genes (e.g., Rag1) that would cripple the immune
system. As a result, the monospecific CD4 T cell popula-
tion only recognizes an antigen from influenza not seen
under normal conditions, and so any CD4 T helper cells
would be unable to provide cognate antigen-specific help
to FliC- or DENV-specific B cells. Since a relatively
normal number of T cells are still produced, all other
components of the immune system, including organized
lymphoid tissues, would still develop normally. Since the
6.5-TCR mice were on a B10.D2 background, B10.D2 mice
were used as WTcontrols.
With an immunization protocol using hFliC filaments
administered IP (priming dose), 6.5-TCR mice were still
capable of producing a strong serum IgM response within
the range of B10.D2 controls (within a two-fold dilution);
no detectable levels of IgA were observed in any condition
(Fig. 5b and Additional file 1: Figures S5a-c). Interestingly,
B10.D2 mice treated with polymeric hFliC in three IP
doses exhibited the most robust IgM and IgG of any group
of mice used in this study (Additional file 1: Figure S5D),
raising the possibility that this protocol was particularly ef-
fective in targeting peritoneal B1 cells. Finally, we wanted
to determine whether differences existed in the IgG iso-
types produced in wild type B10.D2 or the TCR restricted
(6.5-TCR) mice, as the IgG3 subclass has been previously
identified as more prominent in TI antibody responses [9].
B10.D2 mice showed a robust Th1 serum IgG2b response,
with a lower serum IgG3 response (Fig. 5c and Additional
file 1: Figure S5D). Interestingly, although IgG titers were
lower in the 6.5-TCR mice compared to B10.D2 mice
due to the absence of cognate T cell help, 6.5-TCR mice
given hFliC filament IP showed a significant IgG3 re-
sponse (Fig. 5c).
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Fig. 3 Humoral immune response in non-restricted mouse models. a Purified hFliC protein was polymerized in high molar ammonium sulfate
and resulting filaments were pelleted with high-speed centrifugation and resuspended in 150 mM PBS. Under denaturing conditions the major
band was only that of the full-length hFliC (b) Schematic diagram of in vivo immunization protocol used. The immunization period was five
weeks, with four injections spaced a week apart. Priming injection at week zero was either administered IP or IN, and the three subsequent
booster doses where all administered IN. c ELISA scans show serum IgA response in WT C57BL/6 J mice, assayed after the five-week immunization
period. C57BL/6 J mice given polymeric hFliC IN throughout the entire immunization exhibited a strong serum IgA response, while all other mice
showed no IgA titer. d ELISA scans for serum IgG response in WT C57BL/6 J, assayed after the five-week immunization period. C57BL/6 J mice
given polymeric hFliC IP showed a stronger IgG response compared to mice given monomeric hFliC IP. e ELISA scans for serum IgM response in
WT C57BL/6 J mice assayed after the five-week immunization period. Again, C57BL/6 J mice receiving polymeric hFliC IP showed strongest IgM
response. f Serum IgG isotypes were assayed in C57BL/6 J mice, mice given polymeric hFliC IP showed a robust IgG1 response. All groups in
immunization protocols used an n = 3-5 mice per group, and error bars represent the mean +/- SEM, and for statistical analyses, * - p < 0.05;
** - p < 0.005; *** - p < 0.0005. Values were reported as the fluorescence measured in 1:2000 serum dilutions, with background fluorescence
values subtracted
Bennett et al. BMC Biotechnology  (2015) 15:71 Page 6 of 12
Discussion
Taken together, these data suggest that hFliC filaments
are indeed capable of inducing a significant antibody re-
sponse in a T cell restricted model. Development of vac-
cines with multivalent binding (clustering) has largely
been accomplished by the linkage of two proteins in a
linear fashion; however, this method has had limited suc-
cess in certain diseases [27–29]. Thus, the reengineering
of FliC by replacing its solvent exposed FliC D3 domain
with a conformationally intact viral envelope protein
domain may hold promise for an entirely new vaccine
framework. This may be especially important in the
development of vaccines for patients with less robust
immune systems, including those in the early perinatal
period, in people suffering from various T cell im-
munodeficiency disorders (HIV-AIDS, DiGeorge syn-
drome), patients undergoing chemotherapy, as well as
elderly patients with sluggish adaptive immunity.
The increased potency of the hFliC relative to the
monomeric form may relate to multiple factors. In the
polymeric form the antigen may be more able to cross-
link the antigen-specific B cell receptors. As a less soluble
complex the filament may also be more easily taken up by
antigen presenting cells for stimulation of T helper cells.
In addition, the polymeric antigen may also have a greater
potential to recruit the T helper-independent B-1 B cell
population; this is evidenced by the strong IgM and IgG3
response in the 6.5-TCR mice when hFliC filaments were
injected into the peritoneum, where B-1 B cells are
dominant. More detailed studies on the IgM (and IgG3)
response will be helpful in determining any benefit in
recruiting B-1 B cells in protective immunity, as it may
help recruit a distinctive antibody repertoire.
To date no licensed vaccine exists for DENV infection.
This is complicated by the concern that sub-neutralizing
levels of cross-reactive anti-DENV antibodies might re-
sult in more severe disease (i.e., Dengue Hemorrhagic
Fever; [30–34]. Thus, it is crucial to develop a vaccine
framework that is equally effective against all DENV se-
rotypes. Live attenuated tetravalent viruses have shown
only limited success in both non-human primates and
humans, but it has been difficult to establish a proper
balance between immunogenicity and adverse reactions
with these formulations [35, 36]. In addition, while recom-
binant DENV subunit vaccines can induce neutralizing
titers in mice when co-administered with adjuvant [37],
these were found to be less efficacious. Our approach
of reengineering FliC to replace its solvent exposed
FliC D3 domain with antigenic determinants allows us
to combine the benefits of the immunological adjuvant
effects of flagellin with the added immunogenicity of
polymeric vaccine antigens. Moreover, independent
replacement of the FliC D3 domain with envelope pro-
teins from each of the four DENV serotypes, and then
producing mixed filaments with stoichiometric amounts
of each hFliC protein could produce a universal DENV
vaccine with balanced broadly neutralizing capabilities
(i.e. against all serotypes). This strategy may overcome
the problem noted in a recent trial with a tetravalent
recombinant vaccine, in which the response to one
serotype was much lower than the response to the other
serotypes [38].
Fig. 4 Hybrid flagellin filaments are able to crosslink BCR in vitro. a Schematic of how TI immune response is generated. Polymeric antigens bind
to B cell receptors and crosslink them. Once this crosslinking event occurs, the B cell will self-differentiate into plasma cells to produce antibodies.
b 4G2 B cell hybridoma (DENV2-specific IgG producing hybridoma) stimulated with polymeric hFliC. Stimulated cells showed more organized
expression of Ig receptors compared to unstimulated cells, indicating cells were crosslinked (top panel). This was further confirmed by staining
with anti-Histag antibody
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Conclusions
We reengineered the native FliC structure by replacing
the FliC D3 domain to contain a conformationally intact
DENV2 E protein domain, without compromising either
protein’s structure. Moreover, this hybrid protein could
be polymerized to produce filaments capable of stimulating
a humoral antibody response; filaments were found to be
more potent induces of antibody responses than mono-
mers. More importantly, these hybrid protein filaments
were capable of crosslinking B cell antigen receptors in
vitro and accordingly were also shown to induce signifi-
cant antibody responses even in a T cell repertoire-
Fig. 5 Humoral immune response in TI mouse model (6.5-TCR transgenic). a Schematic diagram of in vivo immunization protocol used. The
immunization period was five weeks, with four injections spaced a week apart. Priming injection at week zero was either administered IP or IN,
and the three subsequent booster doses were administered (IN). b ELISA scans of serum IgM in 6.5-TCR and B10.D2 over five-week immunization
period. Only mice given polymeric hFliC IP in the priming dose showed a serum IgM response. All groups B10.D2 mice immunized showed a
strong IgM response. Statistics were determined by unpaired Student’s t-test, p < 0.05 were considered statistically significant, and error bars represent
the mean +/- SEM. c ELISA scans of serum IgG isotypes in 6.5-TCR, and B10.D2 mice. 6.5-TCR mice given polymeric hFliC IP in the priming
dose exhibited a specific IgG3 response, meanwhile B10.D2 mice showed broader subclass distribution (more balanced between Th1 and
Th2). All groups in immunization protocols used an n = 3-5 mice per group, and error bars represent the mean +/- SEM. Values were reported
as the fluorescence measured in 1:2000 serum dilution in the case of IgM and IgG isotypes for B10.D2 immunized mice, and values were
reported as the fluorescence measured in 1:500 serum dilution for IgG isotype for 6.5-TCR immunized mice, with background fluorescence
values subtracted, and for statistical analyses, * - p < 0.05; ** - p < 0.005; *** - p < 0.0005. Arrows show that there was a specifically increased
IgG3 response in 6.5-TCR mice to IP hFliC filament while IgG2b responses were higher to monomer, while by contrast, in B10.D2 mice IgG1
and IgG2a responses were strong to both IP hFliC filament and monomer
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restricted transgenic mouse model. In sum, this study
lays the groundwork for the use of FliC as a vaccine
scaffold for development of novel vaccines for use even
in immunodeficiency settings.
Methods
Design of hFliC protein
Flagellin was PCR amplified from an earlier vaccine de-
sign, where the DENV2 portion was linked to FliC at the
N’ terminal domain through a GS linker. This FliC was
first PCR amplified from genomic DNA isolated from a
culture of S. Typhimurium. Flagellin was PCR amplified
in two fragments. The first piece was amplified using a
forward primer with flanking 5′ BamH1 site and reverse
primer with 3′ flanking Kpn1, EcoR1 site, that had amp-
lified only the first 184 residues. The second piece was
amplified using a forward primer with 3′ flanking Kpn1,
EcoRI site and reverse primer with 5′ Xho1 site, which
amplified residues 285–494 plus a 6x-His tag. These two
pieces were then PCR overlapped. DENV2 E sequence
from a mouse adapted strain [39] was PCR amplified
from the initial clone, and flanking N’ and C’ terminal
GGGSGGGS linkers were then ligated into FliC lacking
D3 via the Kpn1 and Ecor1 sites. Gene constructs were
checked for appropriate sequence throughout the clon-
ing process. This final construct was then ligated into
the pENTR 3C (life technologies) expression vector for
recombination and subsequent expression.
Production and purification of recombinant proteins
(hFliC, FliC and DENV2 E)
Recombinant protein was produced using Baculovirus
expression system. First, cloned cDNA construct was
transfected into SF21 insect cells (Life Technologies) in
Grace’s supplemented or unsupplemented media (Thermo
Scientific) based on manufacturer’s protocol. Resulting pro-
tein viral stocks were then transduced into SF9 insect cells
(Life Technologies), cultured in HyClone SFX-Insect media
(Thermo Scientific), for larger scale production. The insect
cells secreting the protein were cultured at 27 °C, and the
supernatant was harvested after an optimized incubation
period. The native FliC contains a signaling domain
that allows the protein to be secreted, and this signaling
domain was retained in the hFliC protein. As DENV2 E
is a transmembrane protein, a leader peptide was added
to it so that it would be secreted into the culture super-
natant. The insect culture media was filtered before purifi-
cation. Western blot (Life Technologies) was used to verify
protein expression and purity before precipitating protein
from the media with 80 % saturated ammonium sulfate
(Fisher). After a 2 h precipitation at 4 °C, protein was cen-
trifuged at 12,000 rpm for 30 mins to pellet the protein.
The protein pellet was resuspended with 1XPBS + 0.05 %
Tween-20 and dialyzed over night in a porous membrane
with a molecular weight cut off of 12–14,000 (Spectrum-
Labs). Protein was then bound to HisPur cobalt resin
(Thermo Scientific) overnight. Bound protein was eluted
from HisPur resin using increased concentrations of
imidazole. Eluted protein was subjected to a final dialysis
to rid the protein sample of any traces of Tween-20 and
imidazole. The final protein was concentrated using
polyethylene oxide (PEO: Sigma Aldrich). Concentrated
protein was checked for purity using both Coomassie
(Thermo Scientific) and Western blot (1 ° antibody rabbit-
α-Ht (Santa Cruz Scientific) and 2 ° Donkey α-rabbit
@680 nm (Odyssey)), and concentration was quantified
either using BCA or Bradford.
Molecular modeling of FliC and hFliC filaments
The structure of FliC (PDB code 3A5X) and DENV2
(PDB code 1OAN) were obtained from the Protein
Data Bank. The hFliC filament was built using the mo-
lecular structures of the FliC filament and the DENV2
protein. The D3 domain of a FliC monomer was deleted
(residues 185–285), and the coordinates of DENV2 were
manually translated and rotated until the N- and C-
termini of DENV2 were in close proximity to the C- and
N-termini of the end of the D2 domain of FliC. The
linkers between FliC and DENV2 (sequence GGGSGGGS)
were added using Modeller [40].
Polymerization of hFliC or FliC
Based on previous studies, purified FliC or hFliC proteins
samples were diluted in either 3.0 M ammonium sulfate
or sodium citrate [15, 41]. A final buffer concentration of
1.5 M was obtained for each buffer + protein sample. This
molar condition has been suggested to be ideal for FliC
polymerization. Each buffer + protein sample was allowed
to polymerize overnight at room temperature. Polymers
were pelleted with high-speed centrifugation, and washed
in with 150 mM PBS. These samples were then used for
either TEM or vaccination.
Circular dichroism
Circular dichroism was used to determine secondary
structure of the hFliC protein. Spectra were collected for
each protein (FliC, DENV2, hFliC) using Jasco J-815 CD
Spectrophotometer. Measurements were performed at
25 °C in a 1 cm path length cuvette (Varian), over a
wavelength range of 190–260 nm. Protein for circular
dichroism measurements was diluted in water to eliminate
the effects of NaCl absorption, which absorbs strongly at
wavelengths below 190 nm.
Negative stain transmission electron microscopy
For transmission electron microscopy studies, formvar
carbon coated grids (Ted Pella) were glow discharged for
at least 20 s, 3 μl of polymeric sample was then loaded
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onto formvar carbon coated grid, and excess liquid was
removed. Grids were then washed 3 times in PBS. For
viewing in TEM, grids were negatively stained with either
4 % uranyl acetate or 2 % PTA (phosphotungsten acid)
and placed into desiccator until imaged. Micrographs
were obtained using JEM-1011 transmission electron
microscope or PHILIPS TECNAI 12 transmission electron
microscope.
ELISA of hybrid flagellin
ELISAs were performed to see if the hFliC was capable
of binding DENV2 specific antibodies. Briefly, ELISA
plates were coated with either purified hFliC or purified
FliC (negative control) at two different dilutions (1:2 and
1:4) and incubated overnight at 4 °C. Plates were then
washed, blocked and DENV2 specific monoclonal IgA
antibody (at two dilutions) was added and again incubated
overnight. Detection was performed by adding anti-IgA
antibody (Southern Biotech) conjugated to Alkaline Phos-
phatase, and 4-MUP (Life Technologies) was added for
detection by fluorescence.
Design of DENV2 recombinant IgA
We discovered that the 4G2 hybridoma produced 4 dif-
ferent Ig transcripts and multiple peptides, but only one
pair specific for DENV2 E binding. Mass spectrometry
N-terminal protein sequencing results of purified D1-
4G2-4-15 hybridoma (4G2; ATCC# HB-112) antibody
was used to determine the leader peptide nucleotide
sequence of the correct variable regions. These 4G2
Dengue-specific kappa light and IgG2a heavy chain se-
quences were cloned and deposited in Genbank; NCBI
accession code for kappa light chain is KJ438784 and
IgG2a heavy chain is KJ438785. The full-length kappa
sequence was amplified from 4G2 cDNA and cloned
into pCDNA3.1(+) (Life Technologies) using NheI and
EcoRI sites. The heavy chain variable region amplified
from 4G2 hybridoma cDNA was overlapped with the
IgA heavy constant region amplified from BALB/c spleen
cell cDNA [22]. GS linker and 6XHis-tag PCR fragment
was added with the using another round of overlap PCR.
The complete Dengue specific IgA heavy chain was cloned
into pCAG-eGFP-puro by replacing the eGFP with Age1
and Not1 before ligation and transformation [42]. The
Dengue specific IgA heavy chain clone was confirmed by
sequencing.
Production and purification of DENV2 recombinant IgA
Dengue specific kappa light and IgA heavy chain DNA
constructs was stably transfected into the Chinese hamster
ovary cell line (CHO; CHO-K1; ATCC# CCL-61) and
clonally selected via limit dilution under selection media
(F-12 K media (Corning) supplemented with 10 % fetal
bovine serum (Biowest), 1000 μg/ml G418 (Corning),
and 10 μg/ml puromycin (Sigma)). Final highest IgA-
producing clone was adapted to serum free media
(Corning) and used for production. The final clone
was expanded in 40-T150-flasks and overgrown for
one week prior to supernatant collection in serum free
media. One liter of the supernatant media total protein
was used to purify the rIgA (purification step as men-
tioned above). The production yield and purity was deter-
mined by Western blot, Coomassie, DENV2 protein
binding ELISA, and total IgA ELISA quantification.
Immunogold labeling of hybrid flagellin filaments
Immunogold labeling was performed to further confirm
that the DENV2 subunit was presented on the surface of
the filaments. Here, filaments were loaded onto carbon
coated formvar grids. The grids were then incubated in
1XTBST (tris-buffered saline with Tween) with 0.05 %
BSA (Bovine serum albumin) for 30 min. Grids were
washed and incubated with 4G2 (Dengue specific IgG
hybridoma) for two hrs; again the grids were washed
and incubated with Goat anti-mouse IgG conjugated
gold particles (10 nm: Ted Pella). Finally, the grids were
stained with 2 % uranyl acetate and viewed.
B cell crosslinking
Crosslinking studies were performed using a 4G2 B cell
hybridoma (ATCC# HB-112). 4G2 cell line was cultured/
maintained, based on ATCC recommendation, using
Dulbecco’s modified Eagle’s medium (4 mM L-glutamine,
4.5 g/L of glucose,1.5 g/L sodium bicarbonate, and 10 %
fetal bovine serum: Cellgro). Cells were maintained at a
concentration 1 × 106 cells/ ml, and were passed every
three days. To assess if hFliC filaments were able to
crosslink the BCRs of the 4G2 cell line, cells were first
stimulated with a 20 μg dose of hFliC filaments (pre-
pared as mentioned above) for 30 mins under ambient
conditions. After the 30 mins incubation, cells were
washed 3X in 1XPBS. Cells stimulated with hFliC fila-
ment antigen as unstimulated control were then spun
onto glass slides (Superfrost plus, Fisher Scientific)
using a Cytospin (Shandon). Cells were then fixed with
1 % Paraformaldehyde/PBS and then permeabilized first
with cytoskeleton buffer, followed by 0.5 % Tween-20/
PBS and washed with 3X 0.1 % Tween-20/PBS. Cells
were then blocked with 0.1 % Tween-20 Casein solution
(Thermo Scientific) for at least 30 mins. Cells were then
stained with anti-Histag (Santa Cruz Biotechnology) poly-
clonal IgG antibody (@488 nm) for at least 1 h, and again
were washed. For cells stained with anti-histag antibody,
these cells were again washed and secondary antibody was
added (Donkey anti-rabbit @ 647: Life technologies)
Finally, cells were post fixed with 4 % PFA/PBS solutions
and mounted with Prolong Gold antifade reagent (Life
Technologies), which contained DAPI to counterstain the
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nuclei. Images were obtained using a spinning disk BD
CARVII Confocal Imager (BD Biosystems) attached to a
Zeiss Axio Observer inverted microscope. Hardware, in-
cluding microscope, confocal and digital camera (Qimaging
Rolera EMC2) was controlled using Metamorph imaging
software. Images were further optimized using Volocity
deconvolution software.
Immunization protocol
C57BL/6J, B10.D2, 6.5-TCR (Tg(Tcra/Tcrb)1Vbo) mice
were maintained under specific pathogen free colony
conditions at the UC Riverside vivarium. All procedures
were performed in accordance with UCR Institutional
Animal Care and Use Committee (IACUC) and NIH
guidelines. Immunizations were performed over a five-
week period, where the first dose (priming dose) was
administered either through intranasal (IN) or intraperito-
neal (IP) injections. For intranasal injections, a volume of
20 μl containing 20 μg protein was administered (10 μl
containing 10 μg of protein into each nostril). For intra-
peritoneal injections, a volume of 200 μl, again with a total
protein concentration of 20 μg, was injected into the peri-
toneum of mice using a 25 gauge needle. It should be
noted all protein samples were diluted in 1XPBS to its
final protein concentration. All mice were first anesthe-
tized prior to injection. Three subsequent booster doses
were given to all groups of mice via IN injections. Serum
titers were assayed from peripheral blood collected by at
the time points indicated. Mice were humanely sacrificed
under anesthesia and cervical dislocation at the conclusion
of the experiment.
ELISA for quantification of antibody titers
Black flat-bottom plates (Costar) were coated with 10 μg/
ml recombinant DENV2 (prepared as described earlier), in
coating buffer (25 mM Na2CO3, 75 mM NaHCO3, pH 9.5).
Plates were then washed 3X using 1X TBST buffer (50 mM
Tris pH 7.5, 0.28 M NaCl, 6 mM KCl, 0.1 % Tween 20),
using a Biotek ELx405 Automated Plate Washer. Plates
were blocked for 2 h at room temperature in 3 % normal
goat serum (Vector Labs). Samples were first diluted in
blocking solution; serum was diluted 1:2000 and feces were
diluted 1:10. Diluted samples were then two-fold serially di-
luted, and added to coated/blocked plated in triplicate.
After washing, detection was performed with either Rat
anti-mouse IgA-AP (Southern Biotech, diluted 1:1000),
Goat anti-mouse IgM-AP (Southern Biotech, diluted
1:1000), Goat anti-mouse IgG-AP (Southern Biotech,
diluted 1:2000), Goat anti-mouse IgG1-AP (Southern
Biotech, diluted 1:1000), Goat anti-mouse IgG2A-AP
(Southern Biotech, diluted 1:1000), Goat anti-mouse
IgG2B-AP (Southern Biotech, diluted 1:1000), Goat anti-
mouse IgG3-AP (Southern Biotech, diluted 1:1000), in 1X
TBST. For final development, 10 mM 4-MUP (Molecular
Probes) in DMSO diluted 1:25 in substrate buffer (50 mM
K2CO3 2 mM MgCl2, pH 9.8) was added. Fluorescence
was detected 60 min later 360 nm excitation and 460 nm
emission wavelengths on Molecular Devices SpectraMax
M2e plate reader. Raw fluorescence values from the
dilution series were then subtracted from background
fluorescence values.
Statistical tests
In general, groups were tested using Student’s t-test, as
indicated for each experiment in the figure legends,
with a p < 0.05 considered to be a significant difference
for reporting. In the case of ELISA assays, Mann-
Whitney tests were also used with similar results. In
figures, * - p < 0.05; ** - p < 0.005; *** - p < 0.0005. Prism
(GraphPad) software version 5.04 was used for statistical
test calculations.
Human subjects
No research in this report involved human subjects,
human material or human data.
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